Sage Therapeutics (SAGE) Competitors $6.61 -0.19 (-2.79%) Closing price 04:00 PM EasternExtended Trading$6.60 -0.02 (-0.23%) As of 05:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock SAGE vs. AGIO, GLPG, IRON, IDYA, INDV, EWTX, JANX, EVO, IMCR, and MESOShould you be buying Sage Therapeutics stock or one of its competitors? The main competitors of Sage Therapeutics include Agios Pharmaceuticals (AGIO), Galapagos (GLPG), Disc Medicine (IRON), IDEAYA Biosciences (IDYA), Indivior (INDV), Edgewise Therapeutics (EWTX), Janux Therapeutics (JANX), Evotec (EVO), Immunocore (IMCR), and Mesoblast (MESO). These companies are all part of the "pharmaceutical products" industry. Sage Therapeutics vs. Agios Pharmaceuticals Galapagos Disc Medicine IDEAYA Biosciences Indivior Edgewise Therapeutics Janux Therapeutics Evotec Immunocore Mesoblast Sage Therapeutics (NASDAQ:SAGE) and Agios Pharmaceuticals (NASDAQ:AGIO) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, dividends, risk, institutional ownership, analyst recommendations, media sentiment, community ranking, earnings and profitability. Does the media prefer SAGE or AGIO? In the previous week, Sage Therapeutics had 4 more articles in the media than Agios Pharmaceuticals. MarketBeat recorded 11 mentions for Sage Therapeutics and 7 mentions for Agios Pharmaceuticals. Agios Pharmaceuticals' average media sentiment score of 1.41 beat Sage Therapeutics' score of 0.88 indicating that Agios Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sage Therapeutics 8 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Agios Pharmaceuticals 6 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals and insiders believe in SAGE or AGIO? 99.2% of Sage Therapeutics shares are owned by institutional investors. 5.5% of Sage Therapeutics shares are owned by company insiders. Comparatively, 4.3% of Agios Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Is SAGE or AGIO more profitable? Agios Pharmaceuticals has a net margin of 1,845.92% compared to Sage Therapeutics' net margin of -971.50%. Agios Pharmaceuticals' return on equity of -2.51% beat Sage Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Sage Therapeutics-971.50% -68.18% -60.84% Agios Pharmaceuticals 1,845.92%-2.51%-2.26% Which has more risk and volatility, SAGE or AGIO? Sage Therapeutics has a beta of 0.2, meaning that its share price is 80% less volatile than the S&P 500. Comparatively, Agios Pharmaceuticals has a beta of 0.77, meaning that its share price is 23% less volatile than the S&P 500. Do analysts rate SAGE or AGIO? Sage Therapeutics currently has a consensus target price of $8.81, indicating a potential upside of 31.43%. Agios Pharmaceuticals has a consensus target price of $56.00, indicating a potential upside of 86.67%. Given Agios Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Agios Pharmaceuticals is more favorable than Sage Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sage Therapeutics 2 Sell rating(s) 15 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.00Agios Pharmaceuticals 0 Sell rating(s) 4 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.56 Does the MarketBeat Community favor SAGE or AGIO? Sage Therapeutics received 141 more outperform votes than Agios Pharmaceuticals when rated by MarketBeat users. However, 66.76% of users gave Agios Pharmaceuticals an outperform vote while only 64.92% of users gave Sage Therapeutics an outperform vote. CompanyUnderperformOutperformSage TherapeuticsOutperform Votes63364.92% Underperform Votes34235.08% Agios PharmaceuticalsOutperform Votes49266.76% Underperform Votes24533.24% Which has better earnings & valuation, SAGE or AGIO? Agios Pharmaceuticals has lower revenue, but higher earnings than Sage Therapeutics. Sage Therapeutics is trading at a lower price-to-earnings ratio than Agios Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSage Therapeutics$47.40M8.86-$400.67M-$5.80-1.16Agios Pharmaceuticals$37.04M46.91$673.72M$11.242.67 SummaryAgios Pharmaceuticals beats Sage Therapeutics on 13 of the 18 factors compared between the two stocks. Get Sage Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SAGE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SAGE vs. The Competition Export to ExcelMetricSage TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$418.25M$6.47B$5.32B$8.43BDividend YieldN/A2.64%5.21%4.10%P/E Ratio-1.019.0626.7719.71Price / Sales8.86254.27390.22118.35Price / CashN/A65.8538.2534.62Price / Book0.896.416.754.50Net Income-$400.67M$143.98M$3.23B$248.32M7 Day Performance1.44%1.97%1.55%-0.09%1 Month Performance-12.70%4.09%12.22%12.89%1 Year Performance-44.59%-2.83%16.71%7.33% Sage Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SAGESage Therapeutics3.9419 of 5 stars$6.61-2.8%$8.81+33.3%-43.6%$413.93M$47.40M-1.00690Positive NewsAnalyst DowngradeAGIOAgios Pharmaceuticals3.9882 of 5 stars$29.14+6.7%$56.00+92.2%-11.1%$1.69B$37.04M2.57390Positive NewsAnalyst DowngradeGLPGGalapagos0.4868 of 5 stars$25.07-1.0%$25.33+1.1%+2.1%$1.65B$288.19M0.001,310Positive NewsIRONDisc Medicine2.906 of 5 stars$46.61+5.4%$98.80+112.0%+56.4%$1.61BN/A-11.7130IDYAIDEAYA Biosciences3.6695 of 5 stars$18.35+5.3%$53.58+192.0%-53.3%$1.61B$7M-5.5680Positive NewsAnalyst ForecastINDVIndivior3.283 of 5 stars$11.34+2.3%$15.00+32.3%-33.8%$1.56B$1.17B-32.401,164News CoveragePositive NewsEWTXEdgewise Therapeutics2.9421 of 5 stars$14.82+1.6%$40.22+171.4%-18.4%$1.55BN/A-9.8860Positive NewsJANXJanux Therapeutics2.737 of 5 stars$26.06+2.0%$95.25+265.5%-45.5%$1.54B$10.59M-22.2730Positive NewsEVOEvotec1.4989 of 5 stars$4.17-3.0%$5.93+42.3%-21.2%$1.48B$788.22M0.004,200Positive NewsGap DownIMCRImmunocore2.7779 of 5 stars$29.54+4.0%$58.13+96.8%-37.9%$1.48B$310.20M-31.09320Positive NewsMESOMesoblast1.8339 of 5 stars$11.35+3.5%$18.00+58.6%+42.4%$1.45B$5.67M0.0080Gap Down Related Companies and Tools Related Companies Agios Pharmaceuticals Competitors Galapagos Competitors Disc Medicine Competitors IDEAYA Biosciences Competitors Indivior Competitors Edgewise Therapeutics Competitors Janux Therapeutics Competitors Evotec Competitors Immunocore Competitors Mesoblast Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SAGE) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | SponsoredTrump Predicts Dollar DownfallREAD THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... ...Augusta Precious Metals | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | SponsoredElon’s backup plan for AIElon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sage Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sage Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy SAGE Stock Free SAGE Stock Alerts